【JP:4892】Cash flow

Market cap

¥5.1B

P/E ratio

-5.6x

Cyfuse develops 3D tissues and organs made entirely from human cells for regenerative medicine, drug discovery, and medical device applications.

	2020/12	2021/12	2022/12	2023/12	2024/12	2025/12
Depreciation & amortization	33	18	54	38	36	35
Cash from operations	-294	162	-404	-562	-761	-535
Capital expenditures	-0	-	-228	-19	-8	-47
Cash from investing	-0	-51	-431	-19	-9	-398
Proceeds from issuance of term debt, net	470	-	90	-	-	489
Repayments of term debt	-14	-24	-81	-78	-18	-18
Cash from financing	489	229	2,659	18	-52	1,256
Free cash flow		-
FCF margin (%)		-